TW202134243A - 對kras g12d突變具有抑制活性之化合物 - Google Patents

對kras g12d突變具有抑制活性之化合物 Download PDF

Info

Publication number
TW202134243A
TW202134243A TW109141900A TW109141900A TW202134243A TW 202134243 A TW202134243 A TW 202134243A TW 109141900 A TW109141900 A TW 109141900A TW 109141900 A TW109141900 A TW 109141900A TW 202134243 A TW202134243 A TW 202134243A
Authority
TW
Taiwan
Prior art keywords
ring
group
diazabicyclo
compound
methoxy
Prior art date
Application number
TW109141900A
Other languages
English (en)
Chinese (zh)
Inventor
河合祐一
柴田和朗
朝倉大樹
宇野貴夫
相良武
中村昌幸
小早川優
里安 莎拉 霍爾維
Original Assignee
日商大鵬藥品工業股份有限公司
英商亞士德醫療股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商大鵬藥品工業股份有限公司, 英商亞士德醫療股份有限公司 filed Critical 日商大鵬藥品工業股份有限公司
Publication of TW202134243A publication Critical patent/TW202134243A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109141900A 2019-11-29 2020-11-27 對kras g12d突變具有抑制活性之化合物 TW202134243A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2019216165 2019-11-29
JP2019-216165 2019-11-29
PCT/JP2019/049074 WO2021106231A1 (en) 2019-11-29 2019-12-06 A compound having inhibitory activity against kras g12d mutation
WOPCT/JP2019/049074 2019-12-06

Publications (1)

Publication Number Publication Date
TW202134243A true TW202134243A (zh) 2021-09-16

Family

ID=76128832

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109141900A TW202134243A (zh) 2019-11-29 2020-11-27 對kras g12d突變具有抑制活性之化合物

Country Status (6)

Country Link
US (1) US20230348495A1 (cg-RX-API-DMAC7.html)
EP (1) EP4065583A1 (cg-RX-API-DMAC7.html)
JP (1) JP7707189B2 (cg-RX-API-DMAC7.html)
CN (1) CN115003677B (cg-RX-API-DMAC7.html)
TW (1) TW202134243A (cg-RX-API-DMAC7.html)
WO (2) WO2021106231A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI844242B (zh) * 2022-01-21 2024-06-01 大陸商南京明德新藥研發有限公司 橋環取代的雜芳基並吡喃類衍生物及其應用

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
MD4051678T2 (en) 2019-10-28 2026-07-31 Merck Sharp & Dohme Llc Small molecule inhibitors of the KRAS G12C mutant
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
EP4015520B1 (en) * 2019-12-02 2025-02-19 280 Bio, Inc. Oxygen-containing heterocyclic compound, preparation method and application thereof
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
WO2022002102A1 (en) * 2020-06-30 2022-01-06 InventisBio Co., Ltd. Quinazoline compounds, preparation methods and uses thereof
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4208261A1 (en) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
CN116323624B (zh) * 2020-09-30 2026-07-10 上海医药集团股份有限公司 一种喹唑啉类化合物及其应用
US20240034733A1 (en) 2020-11-03 2024-02-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2022105855A1 (en) * 2020-11-20 2022-05-27 Jacobio Pharmaceuticals Co., Ltd. Kras g12d inhibitors
CN116490508A (zh) * 2020-11-20 2023-07-25 北京加科思新药研发有限公司 Kras g12d抑制剂
WO2022105859A1 (en) * 2020-11-20 2022-05-27 Jacobio Pharmaceuticals Co., Ltd. Kras g12d inhibitors
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
US20240092803A1 (en) * 2021-01-08 2024-03-21 Beigene Switzerland Gmbh Bridged compounds as kras g12d inhibitor and degrader and the use thereof
WO2022148422A1 (en) * 2021-01-08 2022-07-14 Beigene, Ltd. Bridged compounds as kras g12d inhibitor and degrader and the use thereof
TWI793999B (zh) * 2021-02-01 2023-02-21 大陸商南京明德新藥研發有限公司 嘧啶並吡喃化合物
WO2022171143A1 (zh) * 2021-02-09 2022-08-18 南京明德新药研发有限公司 5,6,7,8-四氢吡啶[3,4-d]嘧啶化合物
JP2024505594A (ja) * 2021-02-09 2024-02-06 メッドシャイン ディスカバリー インコーポレイテッド ピリミジン芳香環化合物
WO2022170999A1 (zh) * 2021-02-09 2022-08-18 南京明德新药研发有限公司 吡啶[4,3-d]嘧啶类化合物
LT4293024T (lt) 2021-02-15 2026-05-25 Astellas Pharma Inc. Chinazolino junginys, skirtas g12d mutantinio kras baltymo degradacijai sukelti
CA3211110A1 (en) * 2021-02-15 2022-08-18 Astellas Pharma Inc. 4-aminoquinazoline compound
KR20230169967A (ko) * 2021-03-12 2023-12-18 브리스톨-마이어스 스큅 컴퍼니 Kras g12d 억제제
WO2022194066A1 (zh) * 2021-03-15 2022-09-22 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
TWI810803B (zh) * 2021-03-15 2023-08-01 大陸商藥雅科技(上海)有限公司 突變蛋白抑制劑的製備及其應用
WO2022194192A1 (zh) * 2021-03-18 2022-09-22 四川科伦博泰生物医药股份有限公司 一类杂芳环化合物、其制备方法及用途
CN116157400B (zh) * 2021-03-30 2024-10-22 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和用途
WO2022217042A1 (en) * 2021-04-09 2022-10-13 Ikena Oncology, Inc. Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions
WO2022223020A1 (zh) * 2021-04-23 2022-10-27 清华大学 靶向活化与失活态kras g12d的抑制剂
WO2022232331A1 (en) * 2021-04-29 2022-11-03 Amgen Inc. Heterocyclic compounds and methods of use
CN117561063A (zh) * 2021-04-29 2024-02-13 安进公司 杂环化合物及使用方法
EP4332105A4 (en) * 2021-04-30 2025-05-28 Genfleet Therapeutics (Shanghai) Inc. PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, ITS PREPARATION PROCESS AND ITS MEDICAL USE
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
CN115385937A (zh) * 2021-05-25 2022-11-25 江苏恒瑞医药股份有限公司 嘧啶并环烷基类化合物、其制备方法及其在医药上的应用
CN117769554A (zh) * 2021-05-28 2024-03-26 大鹏药品工业株式会社 Kras突变蛋白的小分子抑制剂
CN117500799A (zh) * 2021-06-09 2024-02-02 伊莱利利公司 作为kras g12d抑制剂的取代的稠合吖嗪
WO2022258974A1 (en) * 2021-06-10 2022-12-15 Redx Pharma Plc Quinazoline derivatives useful as ras inhibitiors
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
WO2022262838A1 (en) * 2021-06-18 2022-12-22 Silexon Ai Technology Co., Ltd. Deuterated compounds useful as kras g12d inhibitors
MX2023015533A (es) * 2021-06-21 2024-01-23 Jiangsu Hengrui Pharmaceuticals Co Ltd Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina.
CA3221811A1 (en) * 2021-06-30 2023-01-05 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of kras g12d mutant
WO2023280026A1 (zh) * 2021-07-05 2023-01-12 四川科伦博泰生物医药股份有限公司 杂芳环化合物、其制备方法及用途
WO2023280280A1 (zh) * 2021-07-07 2023-01-12 微境生物医药科技(上海)有限公司 作为KRas G12D抑制剂的稠环化合物
WO2023284730A1 (en) * 2021-07-14 2023-01-19 Nikang Therapeutics, Inc. Alkylidene derivatives as kras inhibitors
WO2023283933A1 (en) * 2021-07-16 2023-01-19 Silexon Biotech Co., Ltd. Compounds useful as kras g12d inhibitors
CN117157292A (zh) * 2021-07-16 2023-12-01 苏州赞荣医药科技有限公司 Kras g12d抑制剂和其用途
WO2023284881A1 (en) * 2021-07-16 2023-01-19 Silexon Ai Technology Co., Ltd. Heterocyclic compounds useful as kras g12d inhibitors
EP4378478A4 (en) 2021-07-27 2025-11-12 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
EP4382133A4 (en) * 2021-08-06 2025-06-18 Interoligo Corporation Pharmaceutical composition for the treatment of triple-negative breast cancer with non-natural nucleic acid ligand as active ingredient
CN116143806A (zh) * 2021-08-08 2023-05-23 上海凌达生物医药有限公司 一类含氮杂环类化合物、制备方法和用途
EP4384522A1 (en) * 2021-08-10 2024-06-19 Erasca, Inc. Selective kras inhibitors
US20240327929A1 (en) * 2021-08-12 2024-10-03 Merck Sharp & Dohme Llc Dosage regimen for administration of belzutifan
WO2023020347A1 (zh) * 2021-08-16 2023-02-23 华润医药研究院(深圳)有限公司 嘧啶并吡啶类化合物及其制备方法和医药用途
WO2023020518A1 (en) * 2021-08-18 2023-02-23 Jacobio Pharmaceuticals Co., Ltd. N-cyclopropylpyrido [4, 3-d] pyrimidin-4-amine derivatives and uses thereof
WO2023020519A1 (en) * 2021-08-18 2023-02-23 Jacobio Pharmaceuticals Co., Ltd. 1, 4-oxazepane derivatives and uses thereof
CN117222646A (zh) * 2021-09-16 2023-12-12 苏州赞荣医药科技有限公司 Kras g12c抑制剂和其用途
WO2023051586A1 (zh) * 2021-09-29 2023-04-06 先声再明医药有限公司 Kras g12d抑制剂化合物及其制备方法和应用
KR20240073115A (ko) 2021-10-05 2024-05-24 미라티 테라퓨틱스, 인크. 이리노테칸과 kras g12d 억제제의 조합 및 관련된 치료 방법
KR20240089340A (ko) 2021-10-05 2024-06-20 미라티 테라퓨틱스, 인크. 범 ErbB 계열 억제제와 KRAS G12D 억제제의 병용 요법
EP4412719A4 (en) * 2021-10-05 2025-08-13 Mirati Therapeutics Inc COMBINATION THERAPIES BASED ON KRAS G12D INHIBITORS AND SHP-2 INHIBITORS
AU2022359282A1 (en) * 2021-10-05 2024-04-11 Mirati Therapeutics, Inc. Combinations of kras g12d inhibitors with pi3ka inhibitors and related methods of treatment
EP4419686A4 (en) * 2021-10-21 2025-10-15 Nanothera Biosciences Inc COMPOSITIONS AND METHODS OF EXTINGUISHING KRAS
CN114057776A (zh) * 2021-10-31 2022-02-18 南京碳硅人工智能生物医药技术研究院有限公司 一种具有抗癌活性的嘧啶并哌啶衍生物的新合成方法
WO2023103523A1 (zh) * 2021-12-09 2023-06-15 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为kras g12d抑制剂
WO2023119677A1 (en) * 2021-12-24 2023-06-29 Astellas Pharma Inc. Pharmaceutical composition comprising a quinazoline compound
CN118434740A (zh) * 2021-12-31 2024-08-02 上海医药集团股份有限公司 一种喹唑啉类化合物及其应用
JP7629580B1 (ja) * 2022-01-21 2025-02-13 ユーシノヴァ・ファーマシューティカルズ・リミテッド ベンゾピリミジン化合物及びその使用
WO2023138524A1 (zh) * 2022-01-24 2023-07-27 贝达药业股份有限公司 Kras g12d降解剂及其在医药上的应用
CA3243798A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras Modulators and Their Uses
US20250154170A1 (en) * 2022-02-10 2025-05-15 Bayer Aktiengesellschaft Fused pyrimidines as kras inhibitors
CA3255513A1 (en) 2022-03-11 2025-03-04 Astellas Pharma Inc. HETEROCYCLIC COMPOUND TO INDUCE DETERIORATION OF G12D MUTATION KRAS PROTEIN
WO2023179629A1 (zh) * 2022-03-22 2023-09-28 苏州泽璟生物制药股份有限公司 取代桥环类抑制剂及其制备方法和应用
CN116891488B (zh) 2022-04-11 2025-12-12 成都海博为药业有限公司 稠环化合物、包含其的药物组合物及应用
US20230365595A1 (en) * 2022-05-13 2023-11-16 Ranok Therapeutics (Hangzhou) Co. Ltd. Inhibitors of kras(g12d)
WO2023230190A1 (en) 2022-05-25 2023-11-30 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
CN114989195B (zh) * 2022-05-25 2024-10-29 广东晨康生物科技有限公司 一种噻吩并嘧啶类化合物或其药学上可接受的盐及其制备方法和应用
CN117164580A (zh) * 2022-05-27 2023-12-05 苏州泽璟生物制药股份有限公司 一种kras g12c抑制剂的制备方法及其中间体
KR20250034963A (ko) * 2022-06-24 2025-03-11 메드샤인 디스커버리 아이엔씨. 헤테로사이클릭 치환 피리미도피란 화합물 및 이의 용도
WO2024019103A1 (ja) 2022-07-21 2024-01-25 アステラス製薬株式会社 G12d変異krasタンパクに作用する複素環化合物
KR20250037564A (ko) * 2022-07-29 2025-03-17 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Kras g12d 억제제를 포함하는 약학적 조성물
TW202412789A (zh) 2022-08-05 2024-04-01 日商安斯泰來製藥股份有限公司 用於誘導突變kras蛋白分解之雜環化合物
AU2023322690A1 (en) * 2022-08-12 2025-03-20 Astellas Pharma Inc. Anti cancer combinations comprising chemotherapy
EP4568674A1 (en) 2022-08-12 2025-06-18 Astellas Pharma Inc. Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity
JP2025528836A (ja) 2022-08-17 2025-09-02 ツリーライン バイオサイエンシズ インコーポレイテッド ピリドピリミジンKRas阻害剤
EP4577214A2 (en) * 2022-08-26 2025-07-02 Merck Sharp & Dohme LLC Small molecule inhibitors of kras proteins
WO2024064335A1 (en) * 2022-09-23 2024-03-28 Ikena Oncology, Inc. Naphthyl-substituted pyranopyrimidinones and related compounds and their use in treating medical conditions
CN117800976A (zh) * 2022-09-30 2024-04-02 上海凌达生物医药有限公司 一类含氮杂环类化合物、制备方法和用途
EP4631942A1 (en) 2022-10-21 2025-10-15 Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. Pan-kras degrading agent, and preparation method therefor and use thereof
CN117917416A (zh) 2022-10-21 2024-04-23 上海领泰生物医药科技有限公司 Kras g12d降解剂及其制备方法和应用
CN116554208A (zh) * 2022-12-02 2023-08-08 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为kras g12d抑制剂
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
EP4680609A1 (en) 2023-03-15 2026-01-21 Quanta Therapeutics, Inc. Kras modulators and uses thereof
TW202438503A (zh) * 2023-03-23 2024-10-01 大陸商南京明德新藥研發有限公司 雜環取代的嘧啶並吡喃類化合物及其應用
CN122180685A (zh) * 2023-03-27 2026-06-09 深圳市原力生命科学有限公司 用于降解和抑制kras(g12d)蛋白的化合物
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
AR133028A1 (es) 2023-06-22 2025-08-20 Astellas Pharma Inc Composición farmacéutica que comprende un degradador de todas las kras
AR133027A1 (es) 2023-06-22 2025-08-20 Astellas Pharma Inc Composición farmacéutica que comprende un compuesto de quinazolina
WO2025019823A1 (en) * 2023-07-20 2025-01-23 Merck Sharp & Dohme Llc Small molecule protein degraders of kras g12d mutant
WO2025026903A1 (en) * 2023-07-31 2025-02-06 Bayer Aktiengesellschaft Imidazo pyrimidine compounds for the treatment of cancer
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
WO2025064848A1 (en) 2023-09-21 2025-03-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyridine kras inhibitors
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20260096846A (ko) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Kras 단백질의 소분자 억제제
WO2025108479A1 (en) * 2023-11-24 2025-05-30 Shenzhen Ionova Life Science Co., Ltd. Compounds for degradation or inhibition of kras mutant proteins and uses thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025218811A1 (zh) * 2024-04-19 2025-10-23 领泰生物医药(绍兴)有限公司 pan-KRAS靶向蛋白降解剂及其制备方法和应用
WO2025230961A1 (en) * 2024-04-29 2025-11-06 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025240740A1 (en) * 2024-05-15 2025-11-20 Merck Sharp & Dohme Llc Small molecule protein degraders of kras g12d mutant
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en) 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
ZA935111B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
PT669929E (pt) 1992-11-13 2007-04-30 Immunex Corp Ligando de elk, uma citoquina
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5516658A (en) 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
EP0729471A1 (en) 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
BR9408323A (pt) 1993-12-17 1997-08-19 Sandoz Ag Derivados de rapamicina
EP0756627A1 (en) 1994-04-15 1997-02-05 Amgen Inc. Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
US6057124A (en) 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
DE69624921T2 (de) 1995-06-09 2003-09-11 Novartis Ag, Basel Rapamycinderivate
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
WO1998002441A2 (en) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Non immunosuppressive antifungal rapalogs
EP0923585B1 (en) 1996-07-18 2002-05-08 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
EP0922030A1 (en) 1996-08-23 1999-06-16 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
HUP0000852A2 (hu) 1997-02-03 2001-05-28 Pfizer Products Inc. Aril-szulfonil-amino-hidroxámsav-származékok, valamint e vegyületeket tartalmazó gyógyászati készítmények
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク N−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
NZ336836A (en) 1997-02-11 2001-02-23 Pfizer Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
US6150395A (en) 1997-05-30 2000-11-21 The Regents Of The University Of California Indole-3-carbinol (I3C) derivatives and methods
TR200000368T2 (tr) 1997-08-08 2000-07-21 Pfizer Products Inc. Ariloksiariarilsülfonilamino hidroksamik asit türevleri.
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
EP1004578B1 (en) 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
NZ516258A (en) 1999-06-07 2004-02-27 Immunex Corp Tek antagonists
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
IL147803A0 (en) 1999-08-24 2002-08-14 Ariad Gene Therapeutics Inc 28-epirapalogs
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
US7074408B2 (en) 2000-02-25 2006-07-11 Immunex Corporation Use of integrin antagonists to inhibit angiogenesis
CA2531454C (en) 2003-07-08 2011-10-25 Novartis Ag Use of rapamycin and rapamycin derivatives for the treatment of bone loss
EP1648900A4 (en) 2003-07-11 2010-02-10 Ariad Pharma Inc PHOSPHORUS MACROCYCLES
TW200523262A (en) 2003-07-29 2005-07-16 Smithkline Beecham Corp Inhibitors of AKT activity
JP4242911B2 (ja) 2004-08-26 2009-03-25 ファイザー・インク プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物
TW200626610A (en) 2004-10-13 2006-08-01 Wyeth Corp Analogs of 17-hydroxywortmannin as PI3K inhibitors
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CN101267824A (zh) 2005-09-20 2008-09-17 辉瑞产品公司 使用酪氨酸激酶抑制剂的治疗剂型和方法
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
CN103459400B (zh) 2011-04-06 2016-05-18 大鹏药品工业株式会社 咪唑并噁嗪化合物或其盐
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
AU2014249233A1 (en) * 2013-03-13 2015-09-24 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
EP3417851B1 (en) 2013-09-09 2020-07-22 Peloton Therapeutics, Inc. Aryl ethers and uses thereof
MX380928B (es) * 2013-10-10 2025-03-12 Araxes Pharma Llc Inhibidores de kras g12c.
AU2016245864C1 (en) * 2015-04-10 2021-09-09 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2017068412A1 (en) 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
KR102932353B1 (ko) * 2015-11-16 2026-02-27 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
ES2863873T3 (es) * 2016-05-18 2021-10-11 Mirati Therapeutics Inc Inhibidores de KRAS G12C
JP2019529484A (ja) 2016-09-29 2019-10-17 アラクセス ファーマ エルエルシー Kras g12c変異体タンパク質の阻害剤
US10377743B2 (en) * 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
JOP20190186A1 (ar) * 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
UA127968C2 (uk) * 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
CN110869358A (zh) * 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
CA3082579A1 (en) * 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
MA52421A (fr) 2018-03-02 2021-01-06 Otsuka Pharma Co Ltd Composés pharmaceutiques
MA53395A (fr) 2018-07-24 2021-06-02 Otsuka Pharma Co Ltd Composés hétérobicycliques pour inhiber l'activité de shp2
WO2020146613A1 (en) * 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN112390797A (zh) * 2019-08-15 2021-02-23 微境生物医药科技(上海)有限公司 新型螺环类K-Ras G12C抑制剂
CN114222743A (zh) * 2019-08-16 2022-03-22 劲方医药科技(上海)有限公司 氧代六元环并嘧啶类化合物,其制法与医药上的用途
CN114615981B (zh) * 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI844242B (zh) * 2022-01-21 2024-06-01 大陸商南京明德新藥研發有限公司 橋環取代的雜芳基並吡喃類衍生物及其應用

Also Published As

Publication number Publication date
CN115003677B (zh) 2024-08-27
US20230348495A1 (en) 2023-11-02
WO2021107160A1 (en) 2021-06-03
WO2021106231A1 (en) 2021-06-03
JP7707189B2 (ja) 2025-07-14
EP4065583A1 (en) 2022-10-05
JP2023512113A (ja) 2023-03-23
CN115003677A (zh) 2022-09-02

Similar Documents

Publication Publication Date Title
JP7707189B2 (ja) Kras g12d変異に対して阻害活性を有する化合物
JP7611978B2 (ja) がんを処置するためのkras g12c阻害剤
JP7361720B2 (ja) がんの治療のためのkras g12c阻害剤
JP7373014B2 (ja) 肺がん、膵臓がん、または大腸がんを治療するためのKRAS G12C阻害剤としての、ベンズイソチアゾール、イソチアゾロ[3,4-b]ピリジン、キナゾリン、フタラジン、ピリド[2,3-d]ピリダジンおよびピリド[2,3-d]ピリミジン誘導体
JP7634003B2 (ja) がんの治療におけるkras g12c及びkras g12d阻害剤として有用なピリドピリミジン誘導体
EP4007752B1 (en) Kif18a inhibitors
JP7095052B2 (ja) Kras g12c阻害剤及びその使用方法
JP7369719B2 (ja) KRas G12C阻害剤及びそれを使用する方法
JP7360396B2 (ja) Kras g12c阻害剤及び同一物の使用方法
US20240246968A1 (en) Small molecule inhibitors of kras g12c mutant
TWI882037B (zh) Kras g12c抑制劑化合物之改善的合成
WO2023097227A1 (en) Small molecule inhibitors of kras mutated proteins
EP4577214A2 (en) Small molecule inhibitors of kras proteins
CN119424423A (zh) 4-氨基丁-2-烯酰胺衍生物及其盐
KR20250164341A (ko) Kras g12c 억제제 화합물의 주요 중간체의 개선된 합성
CN117769554A (zh) Kras突变蛋白的小分子抑制剂
TW202128632A (zh) 4-胺基丁-2-烯醯胺衍生物及其鹽
SG11202109422WA (en) Bicyclic heterocyclyl compounds and uses thereof
JP2022514268A (ja) Kif18a阻害剤
JP2022522777A (ja) 二環式ヘテロアリール化合物及びその使用
CN116003405A (zh) Kras g12c的抑制剂及其使用方法
JP2024516450A (ja) 共有結合性ras阻害剤及びその使用
WO2025019819A2 (en) Small molecule protein degraders of kras g12d mutant
HK40102429A (en) Kras g12c inhibitors for treating cancer
EA049102B1 (ru) Улучшенный синтез соединения, представляющего собой ингибитор kras g12c